BACKGROUND: Pre-hospital platelet inhibition in patients with ST-segment elevation myocardial infarction (STEMI) may improve outcomes. RUC-4 is a novel, second-generation glycoprotein IIb/IIIa inhibitor designed for first-point-of-medical-contact treatment for STEMI by subcutaneous injection. AIMS: The open-label, phase 2A, CEL-02 trial aimed to assess the pharmacodynamics (PD), pharmacokinetics (PK), and tolerability of RUC-4 in STEMI patients undergoing primary PCI (pPCI). METHODS: A total of 27 STEMI patients received a weight-adjusted subcutaneous injection of RUC-4 before pPCI in escalating doses (0.075 mg/kg [n=8], 0.090 mg/kg [n=9], or 0.110 mg/kg [n=10]). RESULTS: The primary PD endpoint of high-grade (≥77%) inhibition of the VerifyNow iso-TRAP assay at 15 minutes was met in 3/8, 7/8, and 7/8 patients in the three cohorts with a dose-response relationship (mean inhibition [min - max] of 77.5% [65.7%-90.6%], 87.5% [73.8%-93.1%], and 91.7% [76.4%-99.3%], respectively; ptrend=0.002). Fifty percent (50%) inhibition remained after 89.1 (38.0-129.7), 104.2 (17.6-190.8), and 112.4 (19.7-205.0) minutes. Injection site reactions or bruising were observed in 1 (4%) and 11 (41%) patients, respectively. Mild access-site haematomas occurred in 6 (22%), and severe access-site haematomas occurred in 2 patients (7%). No thrombocytopaenia was observed within 72 hours post dose. CONCLUSIONS: In patients with STEMI, a single subcutaneous dose of RUC-4 at 0.075, 0.090, and 0.110 mg/kg showed dose-response high-grade inhibition of platelet function within 15 minutes.
BACKGROUND: Pre-hospital platelet inhibition in patients with ST-segment elevation myocardial infarction (STEMI) may improve outcomes. RUC-4 is a novel, second-generation glycoprotein IIb/IIIa inhibitor designed for first-point-of-medical-contact treatment for STEMI by subcutaneous injection. AIMS: The open-label, phase 2A, CEL-02 trial aimed to assess the pharmacodynamics (PD), pharmacokinetics (PK), and tolerability of RUC-4 in STEMI patients undergoing primary PCI (pPCI). METHODS: A total of 27 STEMI patients received a weight-adjusted subcutaneous injection of RUC-4 before pPCI in escalating doses (0.075 mg/kg [n=8], 0.090 mg/kg [n=9], or 0.110 mg/kg [n=10]). RESULTS: The primary PD endpoint of high-grade (≥77%) inhibition of the VerifyNow iso-TRAP assay at 15 minutes was met in 3/8, 7/8, and 7/8 patients in the three cohorts with a dose-response relationship (mean inhibition [min - max] of 77.5% [65.7%-90.6%], 87.5% [73.8%-93.1%], and 91.7% [76.4%-99.3%], respectively; ptrend=0.002). Fifty percent (50%) inhibition remained after 89.1 (38.0-129.7), 104.2 (17.6-190.8), and 112.4 (19.7-205.0) minutes. Injection site reactions or bruising were observed in 1 (4%) and 11 (41%) patients, respectively. Mild access-site haematomas occurred in 6 (22%), and severe access-site haematomas occurred in 2 patients (7%). No thrombocytopaenia was observed within 72 hours post dose. CONCLUSIONS: In patients with STEMI, a single subcutaneous dose of RUC-4 at 0.075, 0.090, and 0.110 mg/kg showed dose-response high-grade inhibition of platelet function within 15 minutes.
Authors: Jieqing Zhu; Won-Seok Choi; Joshua G McCoy; Ana Negri; Jianghai Zhu; Sarasija Naini; Jihong Li; Min Shen; Wenwei Huang; Daniel Bougie; Mark Rasmussen; Richard Aster; Craig J Thomas; Marta Filizola; Timothy A Springer; Barry S Coller Journal: Sci Transl Med Date: 2012-03-14 Impact factor: 17.956
Authors: Marco Valgimigli; Héctor Bueno; Robert A Byrne; Jean-Philippe Collet; Francesco Costa; Anders Jeppsson; Peter Jüni; Adnan Kastrati; Philippe Kolh; Laura Mauri; Gilles Montalescot; Franz-Josef Neumann; Mate Petricevic; Marco Roffi; Philippe Gabriel Steg; Stephan Windecker; Jose Luis Zamorano; Glenn N Levine Journal: Eur Heart J Date: 2018-01-14 Impact factor: 29.983
Authors: Jurriën M ten Berg; Arnoud W J van 't Hof; Thorsten Dill; Ton Heestermans; Jochem W van Werkum; Arend Mosterd; Gert van Houwelingen; Petra C Koopmans; Pieter R Stella; Eric Boersma; Christian Hamm Journal: J Am Coll Cardiol Date: 2010-06-01 Impact factor: 24.094
Authors: Dean J Kereiakes; Tim D Henry; Anthony N DeMaria; Ohad Bentur; Marilyn Carlson; Corinne Seng Yue; Linda H Martin; Jeff Midkiff; Michele Mueller; Terah Meek; Deborah Garza; C Michael Gibson; Barry S Coller Journal: J Am Heart Assoc Date: 2020-08-26 Impact factor: 6.106
Authors: Akshyaya Pradhan; Aashish Tiwari; Giuseppe Caminiti; Chiara Salimei; Saverio Muscoli; Rishi Sethi; Marco Alfonso Perrone Journal: Int J Environ Res Public Health Date: 2022-07-23 Impact factor: 4.614
Authors: Abi Selvarajah; Anne H Tavenier; Enrico Fabris; Maarten A H van Leeuwen; Renicus S Hermanides Journal: J Clin Med Date: 2022-09-23 Impact factor: 4.964